Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia

Raymond P Wu1, Tomoko Hayashi, Howard B Cottam

  • 1Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.

Insights

Electrophilic compounds selectively kill chronic lymphocytic leukemia (CLL) cells by activating the Nrf2 pathway. This mechanism involves Nrf2 signaling, offering a potential therapeutic strategy for CLL.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) cells exhibit elevated reactive oxygen species.
  • The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway regulates oxidative stress response.
  • Nrf2 signaling is elevated in untreated CLL cells compared to normal lymphocytes.

Purpose of the Study:

  • To investigate the molecular mechanism of selective cytotoxicity of redox-active small molecules in CLL.
  • To determine the effect of electrophilic and antioxidant compounds on Nrf2 signaling in CLL.
  • To identify structural classes of compounds that activate Nrf2 and exhibit CLL-selective cytotoxicity.

Main Methods:

  • Tested 27 drug-like compounds from five structural classes: alpha-beta unsaturated carbonyls, isothiocyanates, sulfhydryl reactive metals, flavones, and polyphenols.
  • Assessed compound effects on Nrf2 signaling using a reporter assay and heme oxygenase-1 expression in primary human CLL cells.
  • Determined CLL-selective cytotoxicity and direct binding of compounds to Nrf2 regulators like Keap1.

Main Results:

  • Compounds with alpha-beta unsaturated carbonyls, sulfhydryl reactive metals, and isothiocyanates strongly activated Nrf2.
  • Alpha-beta unsaturated carbonyl compounds demonstrated selective cytotoxicity to CLL cells.
  • Loss of alpha-beta unsaturation abrogated Nrf2 activity and CLL toxicity.
  • Ethacrynic acid and parthenolide activated Nrf2 in normal cells but less potently in CLL cells.
  • Ethacrynic acid directly bound to Keap1 in CLL cells.

Conclusions:

  • Nrf2 signaling is present in human CLL.
  • Altered Nrf2 responses may contribute to the selective cytotoxicity of electrophilic compounds in CLL.
  • Alpha-beta unsaturated carbonyls represent a promising class of compounds for targeting CLL through Nrf2 activation.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...